A biotech firm had grown rapidly without putting in place the processes they needed to get to the next level, finding growth stalled out at a $10 billion valuation.

After getting deep into the financials, we found that the company had almost as any contractors as employees, in an effort to keep overhead down.

It was also apparent they were operating from a defensive keep-things-rolling stance rather than working out what it would take to get the company to a $20 billion cap—a problem we solved for them.



$10 billion



$20 billion

Related case studies